SCHEMBL6359096

SCHEMBL6359096

CC(C)(C)OC(=O)N1CCCC(c2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
LMNA P02545 2/20 0.56
HPGD P15428 1/20 0.56
HIF1A Q16665 1/20 0.56
HPGDS O60760 1/20 0.56
USP30 Q70CQ3 3/20 0.55
GPR119 Q8TDV5 1/20 0.53
TP53 P04637 3/20 0.53
PDE4B Q07343 1/20 0.51
PRMT5 O14744 1/20 0.50
ACKR3 P25106 1/20 0.50
MAPT P10636 1/20 0.50
RORC P51449 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL697513 0.93 TP53 (0.59) ALDH1A1LMNAHPGDHPGDSUSP30
SCHEMBL23951735 0.93 TP53 (0.59) ALDH1A1LMNAHPGDHPGDSUSP30
SCHEMBL1751432 0.93 TP53 (0.59) ALDH1A1LMNAHPGDHPGDSUSP30
SCHEMBL22944633 0.92 USP30 (0.59) ALDH1A1LMNAHPGDHIF1AHPGDS
SCHEMBL24350753 0.90 GPR119 (0.55) ALDH1A1LMNAHPGDHIF1AHPGDS
SCHEMBL22944331 0.90 ALDH1A1 (0.53) ALDH1A1LMNAHPGDHIF1AHPGDS
SCHEMBL22945386 0.89 USP30 (0.64) HPGDSUSP30PDE4BPRMT5ACKR3
SCHEMBL1935816 0.88 HSD11B1 (0.61) ALDH1A1LMNAHPGDHIF1AHPGDS
SCHEMBL20748135 0.88 PDE4B (0.53) ALDH1A1LMNAHPGDHIF1AHPGDS
SCHEMBL28301552 0.88 PDE4B (0.53) ALDH1A1LMNAHPGDHIF1AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 CN disclosed
EP-4138824-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS Anovia Biosciences, Inc. (US) 2023-03-01 EP disclosed
CN-109563094-B (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2022-03-18 CN disclosed
CN-112236423-A Piperidinyl-3- (aryloxy) propanamides and propionates 武田药品工业株式会社 2021-01-15 CN disclosed
US-20170226105-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-10 US disclosed
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226105-A1 TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS MYLK, ROCK1, MYLK2 ALDH1A1 2362/4885LMNA 676/4885HPGD 2893/4885
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 ALDH1A1 199/4885LMNA 4720/4885HPGD 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.